Savara Inc.

NASDAQ:SVRA

3.65 (USD) • At close October 17, 2024
Bedrijfsnaam Savara Inc.
Symbool SVRA
Munteenheid USD
Prijs 3.65
Beurswaarde 600,793,650
Dividendpercentage 0%
52-weken bereik 3.115 - 5.7
Industrie Biotechnology
Sector Healthcare
CEO Mr. Matthew Pauls J.D., M.B.A.
Website https://www.savarapharma.com

An error occurred while fetching data.

Over Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Vergelijkbare Aandelen

Clene Inc. logo

Clene Inc.

CLNN

5.34 USD

Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc.

FENC

4.65 USD

Compugen Ltd. logo

Compugen Ltd.

CGEN

1.73 USD

NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE

6.39 USD

Quipt Home Medical Corp. logo

Quipt Home Medical Corp.

QIPT

3.02 USD

High Tide Inc. logo

High Tide Inc.

HITI

2.55 USD

Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

0.717 USD

Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO

2.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)